Primary ventricular fibrillation and sudden death during a first myocardial infarction: Genetic basis
| ISRCTN | ISRCTN11980212 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11980212 |
| Protocol serial number | 20130005044 |
| Sponsor | Università degli Studi di Pavia |
| Funder | Università degli Studi di Pavia |
- Submission date
- 18/11/2016
- Registration date
- 29/12/2016
- Last edited
- 17/12/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Sudden cardiac arrest (SCA) is a serious medical condition in which the heart suddenly stops beating and is a major cause of death in people across all age groups. There is some evidence suggesting that an inherited predisposition for primary ventricular fibrillation (a heart rhythm abnormality), which occurs in the early stages of a heart attack, could be related to risk of death from SCA. The aim of this study is to look at the relationship between inherited factors (genetic variants) in patients having their first heart attack to with and without ventricular fibrillation.
Who can participate?
Adults aged 75 years or over who have had a heart attack with or without ventricular fibrillation.
What does the study involve?
After agreeing to take part, participants have a blood sample taken which is then frozen. In addition, information about their medical history and personal characteristics is collected using questionnaires. One year later, participants have their medical records reviewed in order to find out how many are still living. The blood samples provided at the start of the study are also tested to find out if there is a link between genes and their risk of developing ventricular fibrillation in the 24 hours following their heart attack.
What are the possible benefits and risks of participating?
There are no direct benefits or risks involved with participating.
Where is the study run from?
Fondazione IRCCS Policlinico San Matteo (Italy)
When is the study starting and how long is it expected to run for?
April 2009 to December 2020
Who is funding the study?
Università degli Studi di Pavia (Italy)
Who is the main contact?
Professor Gaetano Maria De Ferrari
g.deferrari@smatteo.pv.it
Contact information
Scientific
Unità Coronarica LSR Sperimentazione cardiologica
Fondazione IRCCS Policlinico San Matteo
Piazzale Golgi 19
Pavia
27100
Italy
 ORCID ID |
0000-0003-4940-0876 |
|---|---|
| Phone | +39 382 503715 |
| gaetanomaria.deferrari@unito.it |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Multi-centre case-control observational study |
| Secondary study design | Case-control study |
| Study type | Participant information sheet |
| Scientific title | Assessment of genetic predisposition to development of primary ventricular fibrillation in patients with acute myocardial infarction |
| Study acronym | PREDESTINATION |
| Study objectives | The aim of this study is to identify genetic variants that could be involved in the development of ventricular fibrillation in the 24 hours following the first myocardial infarction. |
| Ethics approval(s) | The Bioethics Comittee (IRB) of the Fondazione IRCCS Policlinico San Matteo, 06/04/2009, ref: P-20090008508 Amendment approved: 17/11/2013 |
| Health condition(s) or problem(s) studied | Myocardial infarction |
| Intervention | Following provision of informed consent, all participants have a blood sample taken which is immediately frozen for the future primary outcome analysis. Peripheral blood samples are drawn into n°3 BD Vacutainer blood tubes (containing 3,2% sodium citrate) of 3,5 ml each and immediately stored at -80°C. After a reasonable amount of patients is enrolled (around n°50), Genomic DNA is extracted using a magnetic particle-based methodology (Maxwell 16 Blood DNA purification kit, Promega), according to the manufacturer’s recommendations. All DNAs’ concentrations is determined by spectrophotometry (Nano-Drop, Celbio) and is then normalized at an appropriate concentration for downstream analyses. Information about medical history and demographic data is also collected. Survival status 1 year after the index event will also be collected through medical record review. |
| Intervention type | Other |
| Primary outcome measure(s) |
Genetic loci associated with ventricular fibrillation risk during myocardial infarction are assessed through analysis of 1,536 SNPs (single nucleotide polymorphisms) using the GoldenGate method (Illumina) with a custom-made chip and the Genome Wide Association Study (GWAS) technique at 1 year. |
| Key secondary outcome measure(s) |
1. Relationship between the occurrence of ventricular fibrillation and |
| Completion date | 31/12/2020 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 4000 |
| Key inclusion criteria | Cases: 1. Age between 18 and 75 years, inclusive 2. At least one episode of cardiac arrest due to ventricular fibrillation within 24 h of onset of symptoms of heart attack documented in the index electrocardiogram Controls: 1. Age between 18 and 75 years, inclusive 2. Episode of myocardial infarction within 24 h of onset of symptoms |
| Key exclusion criteria | Case Patients Exclusion criteria: 1. Age younger than 18 or older than 75 years 2. History of previous myocardial infarction 3. Pre-existing significant cardiac disease and / or associated with Ejection Fraction less than or equal to 30% 4. Presence of arrhythmogenic diseases that affect the occurrence of major ventricular arrhythmias (TV, FV) independently by the ischemic event (arrhythmogenic right end/or left ventricular cardiomiopathies, long- and short-QT syndrome; Brugada syndrome and Cathecolaminergic polymorphic ventricular tachicardia) Control Patients Exclusion criteria: 1. Age younger than 18 or older than 75 years 2. History of previous myocardial infarction 3. Pre-existing significant cardiac disease and / or associated with Ejection Fraction less than or equal to 30% 4. Presence of arrhythmogenic diseases that affect the occurrence of major ventricular arrhythmias (TV, FV) independently by the ischemic event (arrhythmogenic right end/or left ventricular cardiomiopathies, long- and short-QT syndrome; Brugada syndrome and Cathecolaminergic polymorphic ventricular tachicardia) |
| Date of first enrolment | 01/09/2009 |
| Date of final enrolment | 01/07/2019 |
Locations
Countries of recruitment
- Italy
Study participating centre
Pavia
27100
Italy
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
17/12/2020: The primary contact email address was changed.
